Letters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. A Tragic, Deadly Denial I read your article in The Washington Post about the woman whose Humana policy required prior authorization for a drug she’d been taking (Bill of the Month:…
As the 2026 midterms approach, health care costs remain voters’ top health priority, but fraud in government health programs, including Medicaid and Medicare, is resonating with Republican voters, 55% of whom say it’s extremely important for candidates to address. Most voters say there is at least “some” fraud in government health programs, but larger shares…
Health care costs top the list of voters’ health care priorities for the midterm elections, though more than half of Republican voters say it is extremely important for candidates to discuss the issue of fraud in government health programs, according to a new KFF Health Tracking Poll. Most voters say there is at least “some”…
By JOHN SAMARAS Ask what Ozempic costs. The honest answer runs from $25 a month to $1,100 a month, and every number in that range is real, published, and defensible. A phrase that covers a forty-four-fold spread is not a price. It is a fog, and patients make four-figure annual decisions inside it. I run…
That is the title of a Journal of Economic Literature article by Gottlieb and Nicholson (2026). Here is a Q&A summary of their article. What are the defining features of physician competition? The authors argue that competition in the physician market is a two-stage process: “First, potential physicians compete to enter medical school and then…
Digital health funding hit $7.4 billion in the first half of 2026, with megadeals absorbing nearly half of all capital. As AI becomes table stakes, founders and investors say the real differentiator is now domain expertise rather than technology. The post ‘The Moat is No Longer Technological’: How Digital Health Fundraising Changed in H1 appeared…
Celcuity drug Revtorpyk is now approved for advanced cases of the most common type of breast cancer that do not harbor a certain mutation. The intravenously infused medicine is first in a new drug class that addresses a pathway associated with many cancers. The post Celcuity’s First-in-Class Drug Gets FDA Approval in Most Common Type…
Neko’s Series C round was co-led by Lightspeed Venture Partners and O.G. Venture Partners, with participation from Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum and BDT & MSD. The post Neko Health Secures $700M to Support US Expansion appeared first on MedCity News.
Medicaid work reporting requirements are moving closer to reality, and healthcare advocates say the operational consequences could be significant
Approximately 12 million people are enrolled in both Medicare and Medicaid, referred to as dual-eligible individuals. This brief examines the demographic, socioeconomic, and health characteristics of dual-eligible individuals compared with Medicare beneficiaries without Medicaid.